Shopping Cart
Remove All
Your shopping cart is currently empty
Emicizumab (Synonyms: RO 5534262, ACE 910)
Catalog No. T77457 Copy Product Info
🥰Excellent
Emicizumab(ACE 910) is a bispecific monoclonal antibody that bridges activated factor IX and activated factor X to mimic the function of activated factor VIII. Emicizumab is used for the prevention and treatment of hemophilia A.
Emicizumab
Copy Product Info🥰Excellent
Catalog No. T77457
Synonyms RO 5534262, ACE 910
Emicizumab(ACE 910) is a bispecific monoclonal antibody that bridges activated factor IX and activated factor X to mimic the function of activated factor VIII. Emicizumab is used for the prevention and treatment of hemophilia A.
Cas No. 1610943-06-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $1,390 | In Stock | In Stock | |
| 5 mg | $2,910 | - | In Stock | |
| 10 mg | $3,930 | - | In Stock | |
| 25 mg | $5,850 | - | In Stock | |
| 50 mg | $7,840 | - | In Stock | |
| 100 mg | $10,600 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.1% (SDS-PAGE); 95.9% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Emicizumab(ACE 910) is a bispecific monoclonal antibody that bridges activated factor IX and activated factor X to mimic the function of activated factor VIII. Emicizumab is used for the prevention and treatment of hemophilia A. |
| In vivo | Emicizumab (1.5-10 mg/kg; i.v.; 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia type A bleeding model with an FVIII equivalent of 9 U/dL.[1]
Emicizumab (3 mg/kg; intravenously) provides additional hemostatic activity when combined with low-dose FVIII (10 U/dL).[1] |
| Synonyms | RO 5534262, ACE 910 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | F9/Factor IX |
| Molecular Weight | 145.14 kDa |
| Cas No. | 1610943-06-0 |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Emicizumab | purchase Emicizumab | Emicizumab cost | order Emicizumab | Emicizumab chemical structure | Emicizumab in vivo | Emicizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.